Corbus: Nectin-4 Targeting Proven With U.S. Data On The Way Early 2025 [Seeking Alpha]
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Last corbus pharmaceuticals holdings, inc. earnings: 3/12 07:05 am
Check Earnings Report
US:NASDAQ Investor Relations:
corbuspharma.com
Company Research
Source: Seeking Alpha
The global urothelial carcinoma market is expected to reach $6.82 billion in 2032. It is expected that the global cervical cancer treatment market could reach $12.63 billion by 2030. Results from the phase 1 U.S. and European study, using CRB-701 for patients with mUC and cervical cancer, expected in Q1 of 2025. Corbus Pharmaceuticals Holdings, Inc. NASDAQ: CRBP ) recently reported positive data from its phase 1 study using CRB-701 for the treatment of patients with metastatic urothelial carcinoma [mUC] and cervical cancer. However, this was data that was reported Recommended For You Recommended For You About CRBP Stock More on CRBP Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
CRBP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRBP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRBP alerts
High impacting Corbus Pharmaceuticals Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
CRBP
News
- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) had its price target raised by analysts at Royal Bank of Canada from $77.00 to $82.00. They now have an "outperform" rating on the stock.MarketBeat
- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) had its price target raised by analysts at Oppenheimer Holdings Inc. from $60.00 to $80.00. They now have an "outperform" rating on the stock.MarketBeat
- SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024 [Yahoo! Finance]Yahoo! Finance
- SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024GlobeNewswire
CRBP
Sec Filings
- 6/18/24 - Form 4
- 6/18/24 - Form 4
- 6/17/24 - Form 8-K
- CRBP's page on the SEC website